Skip to main content
Log in

Role of smooth muscle cell mineralocorticoid receptor in vascular tone

  • Integrative physiology
  • Published:
Pflügers Archiv - European Journal of Physiology Aims and scope Submit manuscript

Abstract

Identification of the mineralocorticoid receptor (MR) in the vasculature (i.e., endothelial and smooth muscle cells) raised the question of its role in vascular function and blood pressure control. Using a mouse model with conditional inactivation of MR in vascular smooth muscle cell (VSMC) (MRSMKO), we have recently shown that the VSMC MR is crucial for aldosterone-salt-induced carotid stiffening. In the present study, we have investigated the specific contribution of the VSMC MR in the regulation of vascular tone in large vessels. In MRSMKO mice, contractions induced by potassium chloride and calcium (Ca2+) are decreased in the aorta, whereas contraction is normal in response to phenylephrine and caffeine. The difference in response to Ca2+ suggests that the VSMC-specific deficiency of the MR modifies VSM Ca2+ signaling but without altering the intracellular Ca2+ store handling. The relaxation induced by acetylcholine is not affected by the absence of MR. However, the relaxation induced by Ach in the presence of indomethacin and the relaxation induced by sodium nitroprussiate are significantly reduced in MRSMKO mice compared to controls. Since endothelial nitric oxide synthase (eNOS) activity is increased in mutant mice, their altered relaxation reflects impairment of the nitric oxide (NO) signaling pathway. In addition to altered NO and Ca2+ signaling, the activity of myosin light chain and its regulators, myosin light chain kinase (MLCK) and myosin phosphatase (MLCP), is reduced. In conclusion, MR expressed in VSMC is required for NO and Ca2+ signaling pathways and contractile protein activity leading to an altered contraction/relaxation coupling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Alvarez Y, Briones AM, Balfagon G, Alonso MJ, Salaices M (2005) Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses. J Hypertens 23:767–777

    Article  CAS  PubMed  Google Scholar 

  2. Barrett KV, McCurley AT, Jaffe IZ (2013) Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol 40:902–909. doi:10.1111/1440-1681.12125

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Birukova AA, Smurova K, Birukov KG, Kaibuchi K, Garcia JG, Verin AD (2004) Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. Microvasc Res 67:64–77

    Article  CAS  PubMed  Google Scholar 

  4. Chataigneau T, Feletou M, Huang PL, Fishman MC, Duhault J, Vanhoutte PM (1999) Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126:219–226. doi:10.1038/sj.bjp.0702300

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. DeLano FA, Schmid-Schonbein GW (2004) Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 11:69–78

    Article  CAS  PubMed  Google Scholar 

  6. Duprez DA (2010) Is vascular stiffness a target for therapy? Cardiovasc Drugs Ther 24:305–310. doi:10.1007/s10557-010-6250-z

    Article  PubMed  Google Scholar 

  7. Feng J, Ito M, Nishikawa M, Okinaka T, Isaka N, Hartshorne DJ, Nakano T (1999) Dephosphorylation of distinct sites on the 20 kDa myosin light chain by smooth muscle myosin phosphatase. FEBS Lett 448:101–104

    Article  CAS  PubMed  Google Scholar 

  8. Funder JW (2013) Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 6:129–138. doi:10.2147/ibpc.S13783

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Funder JW, Mihailidou AS (2009) Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol 301:2–6. doi:10.1016/j.mce.2008.10.029

    Article  CAS  PubMed  Google Scholar 

  10. Galmiche G, Labat C, Mericskay M, Aissa KA, Blanc J, Retailleau K, Bourhim M, Coletti D, Loufrani L, Gao-Li J, Feil R, Challande P, Henrion D, Decaux JF, Regnault V, Lacolley P, Li Z (2013) Inactivation of serum response factor contributes to decrease vascular muscular tone and arterial stiffness in mice. Circ Res 112:1035–1045. doi:10.1161/circres.113.301076

    Article  CAS  PubMed  Google Scholar 

  11. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F (2014) Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 63:520–526. doi:10.1161/hypertension.113.01967

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Hirano K (2007) Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle. J Pharmacol Sci 104:109–115

    Article  CAS  PubMed  Google Scholar 

  13. Isotani E, Zhi G, Lau KS, Huang J, Mizuno Y, Persechini A, Geguchadze R, Kamm KE, Stull JT (2004) Real-time evaluation of myosin light chain kinase activation in smooth muscle tissues from a transgenic calmodulin-biosensor mouse. Proc Natl Acad Sci U S A 101:6279–6284. doi:10.1073/pnas.0308742101

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Levy DG, Rocha R, Funder JW (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89:2736–2740. doi:10.1210/jc.2003-032149

    Article  CAS  PubMed  Google Scholar 

  15. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ (2012) Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18:1429–1433. doi:10.1038/nm.2891

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Mendelsohn ME (2005) In hypertension, the kidney is not always the heart of the matter. J Clin Invest 115:840–844. doi:10.1172/jci24806

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41:19–26

    Article  CAS  PubMed  Google Scholar 

  18. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C, Lacolley P (2006) Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 7:31–39. doi:10.3317/jraas.2006.004

    Article  CAS  PubMed  Google Scholar 

  19. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F (2010) The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J : Off Publ Fed Am Soc Exp Biol 24:2454–2463. doi:10.1096/fj.09-147926

    Article  Google Scholar 

  20. Nguyen Dinh Cat A, Jaisser F (2012) Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 21:147–156. doi:10.1097/mnh.0b013e32834fb25b

    Article  CAS  PubMed  Google Scholar 

  21. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ (2014) Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 34:355–364. doi:10.1161/atvb.113.302854

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Shimizu H, Ito M, Miyahara M, Ichikawa K, Okubo S, Konishi T, Naka M, Tanaka T, Hirano K, Hartshorne DJ et al (1994) Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J Biol Chem 269:30407–30411

    CAS  PubMed  Google Scholar 

  23. Takeda Y (2009) Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res 32:321–324. doi:10.1038/hr.2009.29

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the “Institut National pour la Santé et Recherche Médicale” and grants from the “Agence Nationale pour la Recherche” [ANR09-BLAN-0156-01], the “Centre de Recherche Industrielle et Technique,” and the Fondation de France. A. Tarjus was recipient of a PhD fellowship of the Université Pierre et Marie Curie. E. Belozertseva was recipient of a PhD fellowship of the “Agence Nationale pour la Recherche” [ANR-13-BSV1-0026-01].

Conflict of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frédéric Jaisser.

Additional information

Frédéric Jaisser and Guillaume Galmiche equally contributed to this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 350 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tarjus, A., Belozertseva, E., Louis, H. et al. Role of smooth muscle cell mineralocorticoid receptor in vascular tone. Pflugers Arch - Eur J Physiol 467, 1643–1650 (2015). https://doi.org/10.1007/s00424-014-1616-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00424-014-1616-x

Keywords

Navigation